STAT Plus video chat: What we know about Gilead’s remdesivir data
STAT reported Thursday that a Chicago hospital treating severe Covid-19 patients with Gilead Sciences’ antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week.
What does this early peek at the data tell us? What does it not tell us? And what comes next with clinical trials of remdesivir?
Read Original Article: STAT Plus video chat: What we know about Gilead’s remdesivir data »
